Showing posts with label Virus. Show all posts
Showing posts with label Virus. Show all posts

Jan 17, 2013

Lesser Known C-Diff turns out is more of a Hospital Treat than MRSA.....


There's good and bad news on the "superbug" front. In community hospitals in the Southeast, an easily spread bacterium appears to have overtaken the widely feared MRSA as the most common hospital-acquired infection. But a pilot project in Ohio found that pushing hard on simple things such as hand washing and thorough cleaning can lower rates of that bug significantly.Known as Clostridium difficile, or "C. diff," the bacterium resides in the gut, is spread by contact and can cause painful intestinal infections and in some cases death. It's primarily seen in those over 65, and relapses occur in a fourth of patients, despite treatment.More than 90% of cases happen after antibiotic use, when thC-Diffe healthy flora of the gut are destroyed and C. diff can take up residence.C. difficile was 25% more common than MRSA in a study of 28 hospitals in the Southeast, says Becky Miller, an infectious-disease researcher at Duke UniversityMedical Center in Durham, N.C. The proportions nationwide aren't known.MRSA "was the big bad pathogen in hospitals," but C. diff has overtaken it, Miller says.

She worked the study by looking at C. difficile ra tes at community hospitals in the Duke Infection Control Outreach Network. The data were presented over the weekend at the Fifth Decennial International Conference on Healthcare-Associated Infections conference in Atlanta.Rates of MRSA, or methicillin-resistant Staphylococcus aureus, have been falling nationwide as hospitals increased infection control work, says Jose Cadena, a professor of infectious disease at the University of Texas Health Science Center at San Antonio. MRSA causes serious skin and soft tissue infections. C. diff rates doubled between 1996 and 2003, research has shown.Each year in the USA, more than 28,000 people die of C. diff, according to the Centers for Disease Control and Prevention. The breakdown is:• Hospital-acquired, hospital-onset cases: 165,000 patients, $1.3 billion in excess costs, and 9,000 deaths• Hospital-acquired, post-discharge (up to 4 weeks), 50,000 patients, $0.3 billion in excess costs, and 3,000 deaths.• Nursing home-onset cases, 263,000 patients, $2.2 billion in excess costs, and 16,500 deaths.That is why work in Ohio is so promising. A carefully monitored study of a quarter of the state's hospitals showed that following strict guidelines on hand washing, contact isolation and cleaning caused the number of cases to fall from 7.7 per 10,000 patient days in the hospital to 6.7 between the first and last half of 2009, says Julie Mangino, a professor of internal medicine at Ohio State University Medical Center in Columbus, Ohio."One of the units which was very vigilant had no new cases," she says.

The procedures aren't rocket science: "hand washing before and after room entry, compliance with gown and glove rules and meticulous cleaning," she says. But the researchers actually set up observers, to make sure they were happening. That made the difference.While prevention may seem a no-brainer, it's anything but.C. diff is hugely expensive to treat. Each case of hospital-acquired C. diff is estimated to cost between $4,000 and $9,000 to treat, she says.Many other states also are targeting C. diff prevention, using federal stimulus funds. Ohio and New York were first, but there are about a dozen coming, says the CDC's Nicole Coffin.C. difficile is especially difficult to stop because in addition to being a bacterium, it can exist in a dormant spore form, which can survive for weeks or months on hard surfaces, then begin multiplying when ingested. The alcohol-based hand foams that have become ubiquitous in hospitals don't kill it. It doesn't even appear that soap and water kill the bacteria when it's in spore form.

"But some people think just the physical process of washing gets it off your hands," says Neil Fishman, president of the Society for Healthcare Epidemiology in America.Hospitalization is a double whammy, both because the bacteria can become resident in a given facility and contaminate others and because people in hospitals are already sick and have lower resistance.Judicious antibiotic use is another key factor in lowering rates, says Coffin. "Good" bacteria in the gut can keep C. diff in check. But antibiotics can wipe out those good bacteria, allowing C. diff to flourish.In general, it's hard to convince individuals that they should not take antibiotics unnecessarily, because the threat is a general one — it might in the future render that antibiotic less effective against disease. But in the case of C. diff, it's very immediate. "If you're being treated with antibiotics for something else, you're at higher risk for C diff. It's a big reminder to clinicians that they need to make sure that you're using antibiotics appropriately and judiciously.

Jan 2, 2012

Cases of Tamiflu-Resistant Flu Concern Experts.......




WEDNESDAY, Dec. 28 (HealthDay News) -- World Health Organization researchers are reporting an apparent spike in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug.


The jump in such cases involving the pandemic 2009 A(H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
"In 2007/2008, a different A(H1N1) influenza virus developed Tamiflu-resistance," explained WHO research scientist Aeron C. Hurt, who reported the spike. "On that occasion, it was first detected in large numbers in Europe. However, within 12 months the virus had spread globally, such that virtually every A(H1N1) virus around the world was resistant to this drug," he explained.


"This previous situation demonstrated the speed and potential for a Tamiflu-resistant virus to spread worldwide," Hurt added. "Our concern is that this current pandemic 2009 A(H1N1) Tamiflu-resistant virus may also spread globally."


Hurt, who is based in the Collaborating Centre for Reference and Research on Influenza in North Melbourne, outlined his observations in the Dec. 29 issue of the New England Journal of Medicine.
To explore the question of H1N1-drug resistance, Hurt and his team obtained viral samples from 182 H1N1 flu patients (aged from one month to 74 years) who were being cared for either in an emergency department or an intensive care unit, or by their general practitioner, during the recent winter in Australia.


In all, 29 of the patients (or 16 percent) were found to have a form of H1N1 that was resistant to both Tamiflu (oseltamivir) and an older class of adamantine treatments (rimantadine and amantadine).
Subsequent lab tests revealed that it would take more than 500 times the concentration of Tamiflu usually prescribed for nonresistant flu strains just to cut key aspects of resistant viral activity in half.
On the plus side, however, the resistant strains remained "fully sensitive" to treatment with another drug, Relenza (zanamivir).


Five of the resistant patients were under the age of 5 years. Only one of the patients had been treated with Tamiflu prior to viral sampling, while three had previously been vaccinated with the 2011 influenza vaccine.
The team noted that July marked the high point of resistant cases, most of which were found within a 30-mile or so radius of Australia's seventh-largest urban center, Newcastle. A handful were located in Sydney, the country's largest city.


Raising concerns about the ease of transmission, the investigators noted that some of the resistant cases involved related patients: in four households, two family members had been diagnosed with resistant H1N1. In two other cases, the patients were linked simply by having shared a short car ride.
Hurt pointed out that the resistant strain does not appear to cause more serious illness than "normal" strains, and that no one has died as a result. But he did suggest that the very real prospect that such resistant strains could spread far beyond the shores of Australia is alarming.


"Tamiflu is widely used in the U.S.A. and other parts of the world such as Japan," he noted. "If the virus spreads widely, then there is potential that patients will be treated with a drug that will have little or no benefit. The biggest impact may be in individuals, such as the elderly or immune-compromised, who have a higher risk of complications from influenza infection and most commonly benefit from early and effective antiviral treatment."


Dr. Len Horovitz, a pulmonary specialist with North Shore-LIJ/Lenox Hill Hospital in New York City, explained that, although other non-Tamiflu treatments remain effective, the advent of resistant flu strains can waste valuable time.


"Flu medications have to be given within 24 to 48 hours of the onset of symptoms or they do no good," he said. "So this is a real problem, because we live in a global village. People will get on a plane in Australia and come to my office. This will not be isolated to one part of the world," he added.


"So what I tell people is that immunization is paramount," Horovitz said. "It's important that anybody over the age of 6 months get vaccinated, and that includes pregnant women for whom there is a mercury-free vaccine. If we all did this, we would have very low levels of flu. People wouldn't get it to begin with. And then we wouldn't have to worry whether the drugs we have work or not."